Tag Archives: First

Nabriva scores its first FDA nod with novel antibiotic Xenleta

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up with the challenge. Now, with the FDA’s approval of a new antibiotic for bacterial pneumonia, some of that may change.  Monday, the FDA approved Nabriva Therapeutics’ Xenleta (lefamulin) to treat community-acquired bacterial-pneumonia (CABP) as the first in a new class of antibiotics called pleuromutilins, which… Read More »